Early anticoagulation in patients with acute type B aortic dissection may prove useful until they are treated with a stent-graft or they become stable on medical therapy. Although complete false lumen thrombosis might be a sign of aortic wall healing after stent-grafting, 1, 2 in most situations, thrombosis is incomplete or focal in nature and plays a key role in malperfusion. 3 Thrombosis might develop due to a low-flow pattern within the true or false channel or owing to increased thrombogenicity of subendothelial tissues. Disseminated intravascular coagulation (DIC) has also been reported in acute and chronic dissection, but only minimal data are available. 4 Ischemic complications occur in up to 30% of all cases of type B dissection and are responsible for a high mortality rate. 5 Moreover, partial thrombosis of the false channel has recently been shown to be a significant independent predictor of postdischarge mortality. 6 Surprisingly, until recently, there have been no recommendations about heparinization and/or anticoagulation in acute type B aortic dissection, although anticoagulation has been suggested in certain specific circumstances to avoid thrombosis-related complications. 5, 7 An Internet-based search of Google resulted in .1.5 million hits about aortic dissection, but none addressed this issue, so we feel there is a need to discuss the arguments for and against the institution of anticoagulation in this setting.
What are the deleterious effects of thrombosis and their implications for treatment options and patient outcome? Thrombosis of the false aortic lumen, its side branches (renal and visceral arteries), and/or iliac arteries might induce organ ischemia and/or severe hypertension. 8 This complication has to be resolved without delay to avoid paraplegia, irreversible end-organ ischemia, aneurysm formation, and/or aortic rupture. Thrombosisrelated stenosis of the iliac artery and/or aorta can make stent-graft introduction more difficult. Moreover, expansion of the stent-graft can be impossible or incomplete because of a huge thrombus load within the false lumen. Incomplete stent-graft expansion can lead to additional true lumen obstruction, which might be impossible to relieve by endovascular techniques. Attempts to expand or re-open the true lumen with balloon dilation can lead to embolization of thrombotic material. Similar scenarios are possible when stenting is performed at the level of an abdominal branch (renal or visceral) or iliac artery.
What are the complications related to anticoagulation treatment in acute aortic dissection? The risk of an aortic rupture or massive bleeding if rupture occurs may be increased, but there is no proof to date that anticoagulation increases these risks. Bleeding might be more severe if open surgery has to be performed emergently under heparinization. Since heparin can be com-pletely and immediately reversed by protamine, this is not really an issue. Thrombosis of the false lumen, described as a step to aortic wall healing after stent-graft implantation, is probably delayed or impossible under anticoagulation. Unfortunately, thrombosis onset, location, and extension are unpredictable, and spontaneous thrombosis can be responsible for the complications mentioned above. Since there is absolutely no proof that stent-grafting in combination with anticoagulation in acute aortic dissection leads to poorer outcomes than without anticoagulation, this cannot be a valid argument against anticoagulation.
How should anticoagulation be managed? Low-dose intravenous heparinization at thrombosis prophylaxis doses should be instituted immediately after diagnosis. In uncomplicated patients in whom conservative treatment is intended, oral anticoagulation should be started and heparin maintained until oral anticoagulation is effective. Anticoagulation should be continued for at least 6 weeks, but probably no longer than 3 months. In patients in whom stent-grafting is intended, heparin should be maintained until total re-expansion of the true lumen is observed (without any flow limitation within the aorta, its side branches, or iliac arteries). If residual flow within a dissected aortic segment can be detected, oral anticoagulation should be maintained.
In conclusion, thrombosis in acute aortic dissection plays a key role in malperfusion, which has a high mortality rate. Moreover, partial thrombosis of the false lumen is a predictor of poor survival. Surprisingly, evidence-based recommendations about heparinization and/or anticoagulation in acute type B aortic dissection are so far completely missing. Therefore, the authors would like to provoke the interest of the medical community to perform studies focused on coagulation disorders, thrombosis extension, and anticoagulation in acute aortic dissection, especially of the type B variety.
In the meantime, the authors recommend that heparin treatment be started immediately after type B dissection has been detected. Low-dose prophylactic administration is effective in reducing thrombosis onset or extension and might reduce thrombosis-related complications of acute dissection, at least until stent-grafting has been successfully per-formed. In case of non-aortic bleeding (there is, to our knowledge, no reported bleeding complication induced by heparin treatment in acute type B aortic dissection), coagulation tests should be performed to detect DIC, which would require a more specific administration of anticoagulants. Heparinization should probably be avoided completely in cases of pure intramural and/or periaortic hematoma in the absence of DIC. Since acceptance of our manuscript, we have become aware of a relevant reference ( 
